Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 10880.0
(-2.07%)
KRW 10880.0
(-2.07%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 370.53 Billion | 383.81 Billion | 371.34 Billion | 343.32 Billion | 324.57 Billion | 300.03 Billion |
| Cost of Revenue | 171.57 Billion | 167.78 Billion | 166.94 Billion | 161.61 Billion | 145.8 Billion | 145.74 Billion |
| Gross Profit | 198.96 Billion | 216.02 Billion | 204.4 Billion | 181.7 Billion | 178.77 Billion | 154.29 Billion |
| Operating Expenses | 174.14 Billion | 175.62 Billion | 163.37 Billion | 147.6 Billion | 146.26 Billion | 137.57 Billion |
| Selling, General and Administrative Expenses | 23.51 Billion | 96.56 Billion | 89.8 Billion | 82.46 Billion | 89.36 Billion | 82.12 Billion |
| Research and Development Expenses | 23.74 Billion | 25.96 Billion | 20.19 Billion | 19.72 Billion | 15.84 Billion | 12.84 Billion |
| Other Expenses | 48.05 Billion | 53.09 Billion | 53.37 Billion | 45.42 Billion | 41.04 Billion | -4.64 Billion |
| Cost and Expenses | 345.72 Billion | 343.4 Billion | 330.32 Billion | 309.22 Billion | 292.06 Billion | 283.31 Billion |
| Operating Income | 14.35 Billion | 40.4 Billion | 41.02 Billion | 34.1 Billion | 32.51 Billion | 16.72 Billion |
| Interest Expense | 3.21 Billion | 2.45 Billion | 2.05 Billion | 3.01 Billion | 4.23 Billion | 4.55 Billion |
| Income Tax Expense | 2.93 Billion | 9.59 Billion | 12.97 Billion | 6.84 Billion | 8.06 Billion | 4.81 Billion |
| Earnings before Tax | 12.95 Billion | 41.33 Billion | 38.92 Billion | 28.39 Billion | 27.66 Billion | 8.06 Billion |
| Net Income | -2.5 Billion | 31.74 Billion | 25.95 Billion | 21.54 Billion | 19.59 Billion | -4.89 Billion |
| Earnings Per Share Basic | -139.10 | 1751.18 | 1425.73 | 1183.47 | 1076.32 | -269.00 |
| Earnings Per Share Diluted | -139.10 | 1751.18 | 1425.73 | 1183.47 | 1076.32 | -268.00 |
| Weighted Average Shares Outstanding | 18.01 Million | 18.12 Million | 18.2 Million | 18.2 Million | 18.2 Million | 18.18 Million |
| Weighted Average Shares Outstanding (Diluted) | 18.01 Million | 18.12 Million | 18.2 Million | 18.2 Million | 18.2 Million | 18.25 Million |
| Gross Margin | 0.54 | 0.56 | 0.55 | 0.53 | 0.55 | 0.51 |
| EBIT Margin | 0.04 | 0.15 | 0.14 | 0.13 | 0.13 | 0.08 |
| Profit Margin | -0.01 | 0.08 | 0.07 | 0.06 | 0.06 | -0.02 |
| EBITDA | 15.11 Billion | 51.83 Billion | 48.44 Billion | 38.46 Billion | 39.08 Billion | 20.32 Billion |
| Earnings Before Tax Margin | 0.04 | 0.11 | 0.11 | 0.10 | 0.10 | 0.06 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 82.7 Billion | 78.49 Billion | 104.22 Billion | 370.53 Billion | 100.63 Billion | 85.35 Billion |
| Cost of Revenue | 38.1 Billion | 36.41 Billion | 49.65 Billion | 171.57 Billion | 47.91 Billion | 35.02 Billion |
| Gross Profit | 44.59 Billion | 42.07 Billion | 54.57 Billion | 198.96 Billion | 52.71 Billion | 50.33 Billion |
| Operating Expenses | 41.91 Billion | 39.22 Billion | 45.06 Billion | 174.14 Billion | -44.76 Billion | -47.46 Billion |
| Selling, General and Administrative Expenses | 34.83 Billion | 31.33 Billion | 37.62 Billion | - | 44.76 Billion | 47.46 Billion |
| Research and Development Expenses | 6.38 Billion | 7.32 Billion | 6.31 Billion | - | 6.95 Billion | 7.35 Billion |
| Other Expenses | -685.23 Million | -564.68 Million | -1.11 Billion | -3.69 Billion | -89.53 Billion | -94.93 Billion |
| Cost and Expenses | 80.01 Billion | 75.63 Billion | 94.71 Billion | 345.72 Billion | 47.91 Billion | 35.02 Billion |
| Operating Income | 2.68 Billion | 2.85 Billion | 9.5 Billion | 24.81 Billion | 7.94 Billion | 2.87 Billion |
| Interest Expense | 932.47 Million | 870.29 Million | 891.37 Million | 3.69 Billion | 1 Billion | 1.56 Billion |
| Income Tax Expense | 484.47 Million | 340.08 Million | -1.59 Billion | 2.93 Billion | 1.42 Billion | 1.49 Billion |
| Earnings before Tax | 2.25 Billion | 3.08 Billion | -7.73 Billion | 3.04 Billion | 6.7 Billion | -589.84 Million |
| Net Income | 1.08 Billion | 2.02 Billion | -7.37 Billion | -2.5 Billion | 4.83 Billion | -2.91 Billion |
| Earnings Per Share Basic | 60.42 | 112.61 | -410.62 | - | 268.87 | -161.46 |
| Earnings Per Share Diluted | 60.42 | 112.61 | -410.62 | - | 268.87 | -161.46 |
| Weighted Average Shares Outstanding | 17.97 Million | 17.97 Million | 17.97 Million | 18.01 Million | 17.97 Million | 18.04 Million |
| Weighted Average Shares Outstanding (Diluted) | 17.97 Million | 17.97 Million | 17.97 Million | 18.01 Million | 17.97 Million | 18.04 Million |
| Gross Margin | 0.54 | 0.54 | 0.52 | 0.54 | 0.52 | 0.59 |
| EBIT Margin | 0.05 | 0.06 | 0.11 | - | 0.52 | 0.59 |
| Profit Margin | 0.01 | 0.03 | -0.07 | -0.01 | 0.05 | -0.03 |
| EBITDA | 4.43 Billion | 4.43 Billion | 11.59 Billion | - | 52.71 Billion | 50.33 Billion |
| Earnings Before Tax Margin | 0.03 | 0.04 | 0.09 | 0.07 | 0.08 | 0.03 |
KINO
UD1U
IMC
CHZQ
ORTI-A
THES